MENU
+Compare
PBE
ETF ticker: NYSE ARCA
AS OF
Oct 17 closing price
Price
$72.23
Change
+$0.49 (+0.68%)
Net Assets
226.77M

PBE stock forecast, quote, news & analysis

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index... Show more

Category: #Health
PBE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for PBE with price predictions
Oct 17, 2025

Aroon Indicator for PBE shows an upward move is likely

PBE's Aroon Indicator triggered a bullish signal on September 22, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 241 similar instances where the Aroon Indicator showed a similar pattern. In of the 241 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PBE advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 63 cases where PBE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on October 15, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PBE as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PBE turned negative on October 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PBE broke above its upper Bollinger Band on October 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Illumina (NASDAQ:ILMN), Exact Sciences Corp (NASDAQ:EXAS), Exelixis (NASDAQ:EXEL), BioCryst Pharmaceuticals (NASDAQ:BCRX).

Industry description

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Market Cap

The average market capitalization across the Invesco Biotechnology & Genome ETF ETF is 19.33B. The market cap for tickers in the group ranges from 725.75M to 160.87B. AMGN holds the highest valuation in this group at 160.87B. The lowest valued company is MYGN at 725.75M.

High and low price notable news

The average weekly price growth across all stocks in the Invesco Biotechnology & Genome ETF ETF was 3%. For the same ETF, the average monthly price growth was 4%, and the average quarterly price growth was 23%. XNCR experienced the highest price growth at 13%, while PTGX experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the Invesco Biotechnology & Genome ETF ETF was -3%. For the same stocks of the ETF, the average monthly volume growth was 3% and the average quarterly volume growth was 25%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 66
P/E Growth Rating: 60
Price Growth Rating: 48
SMR Rating: 68
Profit Risk Rating: 71
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
PBE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Powershares Exchange Traded Fund Trust227 E Prairie AveWheaton
Phone
N/A
Web
www.invescopowershares.com